Compare ADMA Biologics Inc (ADMA) vs Broadcom Inc (AVGO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Broadcom Inc — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Broadcom Inc trades at $387.78 (market cap $1.76T). The key difference: Broadcom Inc is far larger — about 826.3× ADMA Biologics Inc's market cap, and Broadcom Inc pays a 0.7% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | AVGO | |
|---|---|---|
Market Cap | $2.13B | $1.76T |
Sector | Health | Technology |
52-Week High | $20.38 | $481.57 |
52-Week Low | $7.60 | $271.80 |
Enterprise Value | $2.20B | $1.81T |
Dividend Yield | — | 0.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Broadcom (AVGO) trades at $370.78, up 2.87% today but remains in a bearish technical trend, 25% below its 52-week high. The company demonstrates strong fundamentals with Q1 2026 EPS beating estimates at $2.44 and robust revenue growth from $51.6B in 2024 to $63.9B in 2025. Recent news highlights a strategic partnership extension with Apple through 2031 for custom AI chips, providing long-term revenue visibility amid a challenging market environment for semiconductor stocks.
AVGO presents a compelling investment case with strong analyst support (88% buy ratings) and a $510.43 consensus price target representing 38% upside. However, elevated valuation multiples (P/E 62.21, P/S 24.17) and technical bearish signals warrant caution. The key opportunity lies in AVGO's AI semiconductor growth (143% YoY to $10.8B last quarter) while risks include market volatility and competitive pressures in the chip sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Broadcom Inc
Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.
Read more on AVGO →
